[Peritoneal mesothelioma: results of a complicated and aggressive procedure incorporating peritonectomy and intraperitoneal hyperthermic chemotherapy, and prospects derived from bench-to-bedside research].
Peritoneal mesothelioma (PM) is a rare primary peritoneal tumor conditioning a very poor quality of life and prognosis. Twenty eight patients (11 men and 17 women) with PM were referred to National Cancer Institute of Milan and submitted to 29 consecutive procedures of peritonectomy and intra peritoneal hyperthermic perfusion (IPHP). Five years overall survival, disease free survival and progression free survival have been 70, 63 and 51%, respectively. Morbidity and toxicity were 14 and 21% respectively. No mortality has been observed peritonectomy associated with IPHP is an effective approach to cure patients PM.
Deraco
M
M
Istituto Nazionale Tumori, Milano.
Kusamura
S
S
Baratti
D
D
Casali
P
P
Zaffaroni
N
N
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D007263:Infusions, Parenteral; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D020360:Neoadjuvant Therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011446:Prospective Studies; D012106:Research; D015996:Survival Rate
D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin